文献速递前列腺癌

基于多参数磁共振成像的风险模型用于活检前判断显著性前列腺癌风险

A multiparametric magnetic resonance imaging-based risk model to determine the risk of significant prostate cancer prior to biopsy.
PubMed 文献 · BJU Int · 2017-03-31

研究基于393例活检前接受多参数磁共振成像(mpMRI)的前瞻性队列开发预测显著性前列腺癌的模型,并在另一机构198例中回顾性外部验证。含mpMRI的进阶模型AUC为0.88,显著高于不含mpMRI变量模型的0.80(P < 0.001),模型校准良好;临床应用可减少28%的活检,同时漏诊2.6%的显著性前列腺癌。

要点

  • 含mpMRI PIRADS评分的进阶模型预测显著性前列腺癌AUC为0.88,高于不含mpMRI变量模型的0.80(P < 0.001)。
  • 模型在内部与外部验证中校准良好。
  • 临床使用该模型可减少28%的活检,同时漏诊2.6%的显著性前列腺癌。

核心结论

  • 纳入mpMRI PIRADS评分与临床数据的个体化风险预测模型可大幅减少不必要的活检,并降低对无临床意义前列腺癌的过度检出,代价是显著性前列腺癌漏诊数量有非常小幅的增加。

研究设计与样本

  • 模型开发基于393例活检前接受mpMRI的前瞻性队列。
  • 外部验证在另一机构198例因前列腺特异性抗原(PSA)异常或直肠指检(DRE)异常而接受mpMRI后活检的男性中回顾性进行。
  • 预测变量包括年龄、PSA水平、DRE、前列腺体积、既往活检和前列腺影像报告与数据系统(PIRADS)评分,采用logistic回归建模,以bootstrap重抽样进行内部验证。

主要发现

  • 393例数据完整者中149例(37.9%)为显著性前列腺癌。
  • 不含mpMRI的变量模型预测显著性前列腺癌AUC为0.80,含mpMRI的进阶模型AUC为0.88,两者差异有统计学意义(P < 0.001)。
  • 模型在内部验证和外部验证中均校准良好。
  • 决策分析显示,实践中使用进阶模型可改善活检结局预测。

关键数值与推荐

  • 显著性前列腺癌定义为Gleason 7且4级成分>5%、阳性针数≥20%或任一针癌组织≥7 mm。
  • 进阶模型预测显著性前列腺癌AUC为0.88。
  • 临床应用该模型可减少28%的活检,同时漏诊2.6%的显著性前列腺癌。

临床怎么用

  • 作者认为,采用纳入mpMRI PIRADS评分和临床数据的预测模型进行个体化风险评估,可大幅减少不必要的活检并降低无临床意义前列腺癌的过度检出。

局限性

  • 外部验证为回顾性进行。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To develop and externally validate a predictive model for detection of significant prostate cancer. PATIENTS AND METHODS: Development of the model was based on a prospective cohort including 393 men who underwent multiparametric magnetic resonance imaging (mpMRI) before biopsy. External validity of the model was then examined retrospectively in 198 men from a separate institution whom underwent mpMRI followed by biopsy for abnormal prostate-specific antigen (PSA) level or digital rectal examination (DRE). A model was developed with age, PSA level, DRE, prostate volume, previous biopsy, and Prostate Imaging Reporting and Data System (PIRADS) score, as predictors for significant prostate cancer (Gleason 7 with >5% grade 4, ≥20% cores positive or ≥7 mm of cancer in any core). Probability was studied via logistic regression. Discriminatory performance was quantified by concordance statistics and internally validated with bootstrap resampling. RESULTS: In all, 393 men had complete data and 149 (37.9%) had significant prostate cancer. While the variable model had good accuracy in predicting significant prostate cancer, area under the curve (AUC) of 0.80, the advanced model (incorporating mpMRI) had a significantly higher AUC of 0.88 (P < 0.001). The model was well calibrated in internal and external validation. Decision analysis showed that use of the advanced model in practice would improve biopsy outcome predictions. Clinical application of the model would reduce 28% of biopsies, whilst missing 2.6% significant prostate cancer. CONCLUSIONS: Individualised risk assessment of significant prostate cancer using a predictive model that incorporates mpMRI PIRADS score and clinical data allows a considerable reduction in unnecessary biopsies and reduction of the risk of over-detection of insignificant prostate cancer at the cost of a very small increase in the number of significant cancers missed.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. van Leeuwen PJ, Hayen A, Thompson JE, et al. A multiparametric magnetic resonance imaging-based risk model to determine the risk of significant prostate cancer prior to biopsy. BJU Int. 2017. PMID: 28207981. doi:10.1111/bju.13814

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。